Search

Your search keyword '"Flamholc L"' showing total 138 results

Search Constraints

Start Over You searched for: Author "Flamholc L" Remove constraint Author: "Flamholc L"
138 results on '"Flamholc L"'

Search Results

1. Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration

2. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

4. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy

5. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study

6. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens

7. The extent of B‐cell activation and dysfunction preceding lymphoma development in HIV‐positive people†

8. Prevalence and Outcomes for Heavily Treatment-Experienced Individuals Living With Human Immunodeficiency Virus in a European Cohort

9. The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study

10. Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress?

11. Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?

12. Observational cohort study of rilpivirine (RPV) utilization in Europe

13. HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe

14. Gender differences in the use of cardiovascular interventions in HIV‐positive persons; the D:A:D Study

15. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

17. Long‐term effectiveness of recommended boosted protease inhibitor‐based antiretroviral therapy in Europe

19. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens

20. Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe

22. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

23. Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe

25. Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort

26. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

27. Liver-related death among HIV/hepatitis C virus-co-infected individuals

28. Sweden, the first country to achieve the Joint United Nations Programme on HIV/AIDS (UNAIDS)/World Health Organization (WHO) 90‐90‐90 continuum of HIV care targets

29. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

30. Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression : A prospective cohort study

31. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study

32. Infection-related and -unrelated malignancies, HIV and the aging population

33. Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors

35. Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study

36. Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfected patients

37. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study

38. Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study

39. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are created equal

40. Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations

41. Development of a definition for rapid progression (RP) of renal function in HIV-positive persons:the D:A:D study

42. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

43. Hepatitis c virus viremia increases the Incidence of chronic kidney disease in HIV-infected Patients

44. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study

45. A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA study

46. A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study

47. History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change

48. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study

49. Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies

50. Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe

Catalog

Books, media, physical & digital resources